Mylan launches new HIV treatment in India
Mylan NV said it is the first company to offer an innovative, reduced-dose HIV treatment in India.
Mylan (Nasdaq:MYL) subsidiary Mylan Pharmaceuticals Private Limited has received marketing authorization from the Drug Controller General of India for its antiretroviral drug Avonza. The fixed-dose combination comprised of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets is recommen ded by the World Health Organization as an alternative first-line regimen for people being treated for…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Patty Tascarella Source Type: news
More News: Health Management | India Health | International Medicine & Public Health | Marketing | Pharmaceuticals | Viread | WHO